MY ACCOUNT | NEWSLETTER |

Peer-Reviewed Study Confirms FeedKind® Pet Protein Is Safe, Well Tolerated and Digestible; Opens the Door for Cultured Protein in Pet Food


Calysta, the global leader in large-scale cultured protein, has published new peer-reviewed research confirming that FeedKind Pet protein is a safe, highly digestible ingredient for adult dogs with promising early signs of supporting gut health.

Published in the journal Animals, the eight-month target animal safety study was designed under FDA Center for Veterinary Medicine guidelines and supports Calysta’s planned GRAS notification for the US market. Thirty-two healthy adult beagles were fed diets containing up to 8% FeedKind Pet protein for six months, followed by a two-month period on a control diet.

The results reaffirm that FeedKind Pet protein can be safely included in dog food, maintaining healthy weight and body condition scores throughout, with no impact on feed intake and high digestibility. Protein and energy digestibility exceeded 80%, and fat digestibility exceeded 90%. The study also revealed positive shifts in the dogs’ fecal microbiome, increasing alpha diversity, an early sign of potential gut health benefits.

Key findings from the study:

  • Long-term safety confirmed: All dogs maintained normal health, weight, and body condition.
  • High digestibility: Protein and energy digestibility consistently above 80%, fat above 90%.
  • No feed intake impact: Dogs readily accepted FeedKind Pet at all inclusion levels.
  • Positive microbiome effect: Inclusion increased alpha diversity and promoted healthy bacteria, signs of gut health support.

Alan Shaw, CEO and Co-Founder of Calysta, said: "This new peer-reviewed research is the most robust and longest study we’ve ever done on FeedKind Pet protein, adding to years of evidence showing it is a safe, high-quality protein source for animals. A science and safety focus has been key to our journey from pilot production to the thousands of tonnes shipped this year. For the pet food industry, FeedKind Pet is a pioneering cultured protein ingredient that brings real innovation and new formulation choices, backed by proven performance and supply security."

Herman Sloot, VP of Global Sales at Calysta, added: "Customers in Europe are already using FeedKind Pet protein to strengthen supply chains and deliver high-quality nutrition for pets. This latest long-term study sets us up to meet the requirements for US GRAS status and gives our customers the confidence to plan for global availability; knowing they have a secure, well-tolerated protein source that works for pets and owners everywhere."

Produced by natural fermentation, FeedKind Pet requires no arable land and minimal water, providing pet food manufacturers with a stable, scalable supply of protein that does not compete with human food resources. Building on the proven success of FeedKind Aqua, Calysta is ready to supply FeedKind Pet at scale as global demand grows for reliable, high-quality protein ingredients.

About Calysta

Calysta, Inc., San Mateo, CA, is a large-scale protein producer and innovator working towards a future where the world’s growing population has guaranteed food security. Calysta makes protein without limits by fermenting low-cost carbon to create new feed and food products. Calysta’s sustainable protein ingredients add to the global food supply.

FeedKind® protein is made using very little water and no agricultural land by fermenting carbon to create a safe, nutritious, and traceable protein. Cultured via natural fermentation, it is non-GMO, has a complete amino acid profile, is highly digestible, and helps promote a healthy gut.


Source: www.calysta.com

Like0
Dislike0
  • Please enter a comment


Name *
Email address *
Comment *


* Required fields

Information on the processing of your personal data
We inform you that, in compliance with the provisions of current national and European regulations for the Protection of Personal Data and Services of the Information Society and Electronic Commerce, by sending us this form you are expressly giving your consent to Grupo Asís Biomedia , SL, (hereinafter, "ASIS GROUP") so that, as the person in charge, it may process your personal data in order to respond to your request for contact and information by electronic means.

Likewise, when you expressly consent, we will process your personal data to send you specialized information, newsletters, offers and exclusive promotions from GRUPO ASIS and related companies.

For the aforementioned purpose, GRUPO ASIS may transfer your data to other companies linked to GRUPO ASIS or to third party service providers for the management of electronic communications and other security services, even in cases where they are outside of the European Union, provided that they legally guarantee the adequate level of protection required by European regulations.

At any time you can withdraw the consent given and exercise the rights of access, rectification, deletion, portability of your data and limitation or opposition to its treatment by contacting GRUPO ASIS by sending an email to protecciondatos @ grupoasis.com, or by written communication to address at Centro Empresarial El Trovador, 8th floor, office I, Plaza Antonio Beltrán Martínez 1, 50002, Zaragoza (Spain), indicating in either case the Ref. Personal data and the right you exercise, as well as attaching a copy of your ID or replacement identification document.


I have read and accept the treatment of my data according to the informed purpose and according Legal notes and the Privacy Policy
I wish to receive commercial information from GRUPO ASIS and related companies



More news

Innovations in animal health: artificial intelligence-enhanced hematocrit analysis for rapid anemia detection in small ruminants

Like0
Dislike0

Drug dose and drug choice: Optimizing medical therapy for veterinary cancer

Like0
Dislike0

The Advantage of FLASH Radiotherapy Confirmed in Mini-pig and Cat-cancer Patients

Like0
Dislike0

NC State Student Creates Coloring Book to Help Children Picture Possibilities in Veterinary Medicine

Like0
Dislike0

UltiMed Expands Syringe Portfolio with Launch of UltiCare® VetRx General Syringes

Like0
Dislike0

Newsletter

 
 

News of interest

EVENTS

Copyright © 2025 - All Rights Reserved
ISSN 2768-198X

Top